What is Paragonix Technologies?
Paragonix Technologies specializes in developing and providing advanced organ preservation technology and services designed to optimize the transplantation process. Their product suite includes innovative devices such as SherpaPak for cardiac transport, LIVERguard, BAROguard, and KidneyVault, all engineered to maintain ideal conditions during organ transit. The company extends comprehensive support to healthcare professionals and transplant centers globally, offering real-time monitoring, case logistics management, and round-the-clock clinical assistance. Through a commitment to clinical research, Paragonix aims to elevate post-transplant outcomes and establish new benchmarks for care in the transplantation sector.
How much funding has Paragonix Technologies raised?
Paragonix Technologies has raised a total of $25.3M across 3 funding rounds:
Debt
$1.1M
Debt
$150K
Series B
$24M
Debt (2013): $1.1M, investors not publicly disclosed
Debt (2020): $150K led by PPP
Series B (2023): $24M supported by Signet Healthcare Partners
Key Investors in Paragonix Technologies
Signet Healthcare Partners
Signet Healthcare Partners is an established provider of growth capital to innovative healthcare companies, focusing on commercial-stage entities in the pharmaceutical and medical device sectors. They actively partner with their portfolio companies to drive value.
PPP
Public-Private Partnership
What's next for Paragonix Technologies?
The recent major strategic investment signals a period of accelerated growth and market expansion for Paragonix Technologies. This capital infusion is expected to fuel further research and development into next-generation organ preservation solutions, enhance global distribution networks, and potentially support strategic partnerships within the healthcare ecosystem. The company's focus on improving transplant success rates positions it for continued leadership and innovation in a field with profound humanitarian impact.
See full Paragonix Technologies company page
